ERBB2 and breast carcinoma: HER2 overexpression in breast cancer identifies patients who benefit from trastuzumab, while PD-L1 (Programmed death-ligand 1) expression serves as a marker to guide checkpoint inhibitor therapy in immuno-oncology [1,5].